Platelets in Patients with Premature Coronary Artery Disease Exhibit Upregulation of miRNA340* and miRNA624* by Sondermeijer, Brigitte M. et al.
Platelets in Patients with Premature Coronary Artery





2, Maurice W. J. de Ronde
1, Arnoud A.
Marquart
3, Anke J. Tijsen
2, Ties A. Mulders





1, Mieke D. Trip
1, Perry D. Moerland
4, Joost C. M. Meijers




1Department of VascularMedicine, Academic MedicalCenter, University of Amsterdam, Amsterdam, TheNetherlands, 2HeartFailure Research Center, Academic Medical Center,
University of Amsterdam, Amsterdam, The Netherlands, 3Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The
Netherlands, 4Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Abstract
Background: Coronary artery disease (CAD) is the leading cause of human morbidity and mortality worldwide, underscoring
the need to improve diagnostic strategies. Platelets play a major role, not only in the process of acute thrombosis during
plaque rupture, but also in the formation of atherosclerosis itself. MicroRNAs are endogenous small non-coding RNAs that
control gene expression and are expressed in a tissue and disease-specific manner. Therefore they have been proposed to
be useful biomarkers. It remains unknown whether differences in miRNA expression levels in platelets can be found
between patients with premature CAD and healthy controls.
Methodology/Principal Findings: In this case-control study we measured relative expression levels of platelet miRNAs
using microarrays from 12 patients with premature CAD and 12 age- and sex-matched healthy controls. Six platelet
microRNAs were significantly upregulated (miR340*, miR451, miR454*, miR545:9.1. miR615-5p and miR624*) and one miRNA
(miR1280) was significantly downregulated in patients with CAD as compared to healthy controls. To validate these results,
we measured the expression levels of these candidate miRNAs by qRT-PCR in platelets of individuals from two independent
cohorts; validation cohort I consisted of 40 patients with premature CAD and 40 healthy controls and validation cohort II
consisted of 27 patients with artery disease and 40 healthy relatives. MiR340* and miR624* were confirmed to be
upregulated in patients with CAD as compared to healthy controls in both validation cohorts.
Conclusion/Significance: Two miRNAs in platelets are significantly upregulated in patients with CAD as compared to
healthy controls. Whether the two identified miRNAs can be used as biomarkers and whether they are cause or
consequence of the disease remains to be elucidated in a larger prospective study.
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Introduction
Coronary artery disease (CAD) is the leading cause of human
morbidity and mortality world wide, underscoring the need for
innovative diagnostic strategies. Prevention of CAD relies on the
accurate identification of individuals at risk of developing CAD. At
present CAD risk estimation is based on the assessment of established
risk factors using one of the available risk assessment algorithms[1].
However, risk estimates are imprecise in predicting which subjects
will develop CAD underscoring the need for innovative diagnostic
strategies[2–4]. This has prompted the search for novel diagnostics
that can improve the identification of individuals at risk of developing
CAD. We propose that, in this respect, microRNAs (miRNAs) could
be highly useful. MiRNAs are a class of endogenous short (,22
nucleotides), single-stranded and non-coding RNA molecules, which
can affect the expression of many mRNAs. They exert coordinated
and potent effects on cell function[5,6] and are implicated in human
diseases[7] including cardiovascular diseases (CVD) [8,9]. According
to current estimates, the human genome is estimated to encode up to
500 miRNAs[10], many of which are expressed in a tissue- and cell-
specific manner[11–14], making them attractive biomarkers for
diagnostic strategies.
Activated platelets play a critical role in the pathophysiology of
CAD in the process of acute thrombosis which follows plaque
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exemplified by the beneficial effects of anti-platelet therapy in both
the acute and chronic phases of the disease. MiRNAs are known
to be present in platelets and exert important regulatory func-
tions[16], since platelets also harbour Dicer and Argonaute 2
(Ago2) complexes, which are involved in the processing of miRNA
precursors and the control of specific transcripts. Until recently,
miRNAs were thought to be present only in tissue and therefore
the use of these molecules as biomarkers for CAD would be less
practical. It is now clear that miRNAs are also present in the
circulation in nucleated blood cells and even in plasma[17,18] and
non-nucleated cells, such as erythrocytes[19] and platelets[16,20–
23], making them easily accessible.
Given the importance of platelets in CAD, we hypothesized that
platelets from patients manifest different miRNA expression
patterns in CAD patients compared to controls. Therefore, we
examined the expression levels of platelet miRNAs in patients with
CAD and compared them with healthy individuals.
Methods
Study populations
The array cohort. For the miRNA array study population
we selected a cohort of 12 Caucasian male patients with CAD at a
young age (premature CAD) and a positive family history of
premature cardiovascular disease (CVD), see Definitions S1.
These patients are genetically predisposed for CAD leading to a
substantial risk for CAD[23]. The patients were selected from the
outpatient clinic of the Academic Medical Center (AMC) of
Amsterdam, which is specialised in premature CAD. Data
collection was done 3.962.0 years after the diagnosis of CAD.
The control cohort was composed of 12 healthy Caucasian male
volunteers, who were recruited by advertisement and who were
matched with the cases for age and smoking habits. Individuals of
this control cohort did not have a history of CVD, nor did they
have a positive family history of CVD and they were not allowed
to use any medication. Patients and controls were excluded when
they suffered from diabetes.
The validation cohorts
To validate the findings of the microarray data, we measured
the expression levels of the selected miRNAs in isolated platelets in
two independent validation cohorts by qRT-PCR.
Validation cohort I. Validation cohort I consisted of 40
premature male CAD subjects and 40 age-matched male controls.
Participants were selected in the same way as the population used
for the miRNA array analysis, using identical matching inclusion
and exclusion criteria. Individuals in the control cohort were again
recruited by advertisement. Data collection was done 5.663.5
years after the diagnosis of CAD. Inclusion took place from
December 2009 to June 2010. Since miRNA expression levels
are influenced by medication [24,25] use we assessed miRNA
expression before and after medication use. Therefore, we asked
twenty-seven control subjects in this cohort, which are part of a
future array study in monocytes, plasma and platelets, to take
simvastatin 40 mg once daily for 6 weeks. During the last two
weeks acetyl salicylic acid 100 mg once daily was added to the
simvastatin. For that matter, they came twice to the clinic.
Validation cohort II. Validation cohort II consisted of mem-
bers of 4 families with high prevalence of premature CAD; 27
atherosclerotic patients and 40 healthy family members. These 4
families were screened at the outpatient clinic. Family members
without signs or complaints of CAD underwent a coronary CT-
scan to assess subclinical CAD. Cases were defined as having a
history of CAD or a coronary calcium score .80
th percentile[26].
Controls were defined as having no signs or complaints of CAD
and a coronary calcium score ,80
th percentile.
Ethics Statement
This study complies with the Declaration of Helsinki. The study
protocol was approved by the Medical Ethical Commission of the
AMC in Amsterdam and written informed consent was obtained
from all subjects.
Peripheral blood collection and platelet isolation
Non-fasting venous blood samples were drawn without stasis
from an antecubital vein, with use of a 19-gauge needle. Blood was
collected in 5 trisodium citrate tubes (each 5 ml containing 0.5 ml
0.105 M trisodium citrate, BD Vacutainer). The first sample was
discarded. Immediately after blood withdrawal, the samples were
centrifuged (180 g, 15 min, room temperature, no brake) to obtain
platelet-rich plasma (PRP). With a polypropylene pipette, the
upper layer of PRP was carefully transferred to a plastic tube to
avoid leukocyte contamination. One part of acid–citrate–dextrose
(ACD) buffer (0.085 M trisodium citrate, 0.11 M glucose,
0.071 M Citric acid) was added to five parts of PRP and then
the PRP was centrifuged (800 g, 20 min, room temperature, no
brake). The platelet-poor plasma was discarded and the platelet
pellet carefully resuspended in Tyrode buffer (136.9 mM NaCl,
2.61 mM KCl, 11.9 mM NaHCO3, 5.55 mM Glucose, 2 mM
EDTA, pH 6.5). The platelet suspension was centrifuged (800 g,
20 min, room temperature, no brake). The supernatant was
discarded and the platelet pellet was resuspended in 50 ml sterile
phosphate buffered saline (PBS) and stored at 280uC prior
to RNA isolation. The isolated platelets were investigated by
fluorescence-activated cell sorting (FACS) using monoclonal
antibodies against CD45 (BD Biosciences), CD235a (DAKO)
and CD61 (BD Biosciences) to identify leukocytes, erythrocytes
and platelets. The purity of the isolated platelets was 99.72% by
FACS analysis. For information about peripheral blood collection
and platelet isolation of the validation cohorts, see Methods S1.
RNA isolation
Platelet RNA was isolated using the mirVana PARIS kit
(Ambion, Inc.), according to the manufacturer’s protocol for
liquid samples. The protocol was modified such that samples were
extracted twice with an equal volume of acid-phenol chloroform
and the column was dried for 3 minutes after the last washing step
and before elution. Samples were concentrated from 50 mlt o
12 ml, of which 5 ml was used for Illumina arrays as described
below.
MiRNA arrays
MiRNA expression profiles were obtained using Illumina
Human v2 MicroRNA Beadarrays according to the manufactur-
er’s recommendation (Illumina, Inc., San Diego, CA) at ServiceXS
(Leiden, The Netherlands). For detailed information of the
MiRNA expression profiling see Methods S1. Raw data were
pre-processed, summarized, log-transformed and quantile normal-
ized using the beadarray package (version 1.12.1) in the statistical
software package R (version 2.9.0). Differential expression was
assessed using a moderated t-test (limma package version 2.18.3).
MiRNAs were considered significantly differentially expressed if
the P-values, adjusted for multiple testing by using Benjamini and
Hochberg’s method, were less than 0.05. Differentially expressed
miRNAs (adjusted p,0.05) were visualized by hierarchical
clustering of the samples (Euclidean distance, complete linkage).
Platelet miRNAs in Coronary Artery Disease
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in the a MIAME compliant database GEO, as detailed on the
MGED Society website http://www.mged.org/Workgroups/
MIAME/miame.html. For a more detailed description of the
microarray analysis, see Methods S1.
Validating miRNA expression by real-time PCR.
The methods for expression analysis by real-time PCR and the
miRNA primers sequences are described in the Methods S1.
Results
Clinical characteristics
The clinical characteristics of the miRNA array cohort and both
the validation cohorts are shown in Table 1. Individuals in the array
cohort had a mean age of 45.566.6 years and did not differ between
patients and controls. The average age of onset of CAD in patients
was 4267.6 years. This cohort consisted of 12 controls and 12
selected patients with premature atherosclerosis. Half of the
patients presented with a myocardial infarction and half of them
with stable angina. The time of data collection was on average
3.962.0 years after the diagnosis of CAD.
Individuals in validation cohort I had a mean age of 51.264.6
years at data collection and did not differ between patients and
controls. Furthermore, the average age of onset of CAD in patients
was 44.963.8 years. This cohort consisted of 40 selected patients
with premature CAD and 40 healthy age matched controls. Half of
the patients presented with a myocardial infarction and half
of them with stable angina. The time of data collection was on
average 5 years after the diagnosis of CAD. Smoking was
significantly higher among patients as compared to controls.
In validation cohort II which was a random sample of families from
our outpatient clinic and was the only cohort without a matched
control group, individuals had a mean age of 46.6615.1 years.
This cohort was composed of 4 families and consisted of 27
patients and 40 healthy family members. The age of the cases and
controls was 59.469.8 and 37.7611.2 respectively. This was
significantly different due to the fact that this cohort was composed
of subjects from three generations. Furthermore, smoking and a
history of hypertension were also significantly different between
patients and controls (all; p,0.05). The average age of onset of
CAD in patients was 50.569.3 years. About 30% of patients
presented with a myocardial infarction and 48% had stable
angina. The remaining 22% had non-coronary vascular disease.
The time of data collection was on average 5 years after the
diagnosis of CVD.
MiRNA profiles of platelets of CAD patients
Each Illumina beadarray contained 1146 human miRNAs as
annotated in the Sanger miRBase 12.0 (see Data S1). In total we
identified 214 miRNAs, which where differentially expressed in
platelets from CAD patients as compared to controls (Data S1).
Supervised hierarchical clustering analysis of these 214 miRNAs
showed distinct patterns of miRNA expression levels between
CAD patients and healthy controls (figure 1). Interestingly, the
hierarchical clustering analysis showed differential expression
between patients with a myocardial infarction as compared to
patients with stable angina. Because of the small number of
subjects, this did not reach statistical significance.
Out of the 214 miRNAs identified in the microarray profiling
analysis, 9 miRNAs were at least 1.5-fold upregulated and
4 miRNAs were at least 1.5 fold downregulated in patients as
compared to controls. Since the hierarchical clustering data
showed 1 patient to cluster within the control group and 1 control
subject to cluster within the patient group, we also analysed our
data without these 2 subjects, to minimize influences of these 2
misclassified subjects (figure 1, green and blue subject). After all the
analysis, six out of 9 miRNAs remained significantly and more
than 1.5 fold upregulated (miR340*, miR615-5p, miR545:9.1,
miR451, miR454* and miR624*) and 1 out of 5 miRNA remained
significantly and more than 1.5 fold downregulated (miR-1280) in
both analyses (figure 2).
Table 1. Characteristics of the subjects.
Microarray Real-Time PCR
Validation cohort I Validation cohort II
Patient n=12 Control n=12 Patient n=40 Control n=40 Patient n=27 Control n=40
Age at data collection. yrs 6 SD 45.766.5 45.467.0 51.464.7 51.064.6 59.469.8 37.7611.2*
Age at onset of CAD. yrs 6 SD 4267.6 - 44.963.8 - 50.569.3 -
CAD defined as AMI. n (%) 6 (50) - 20 (50) - 8 (30) -
CAD defined as stable angina. n (%) 6 (50) - 20 (50) - 13(48) -
Time from diagnosis. yrs 6 SD 3.962.0 - 5.663.5 - 8.669.9 -
Current Smoking. n (%) 1 (8) 1 (8) 11 (28) 5 (13) 12 (44) 11 (27.5)
Smoking at time of event. yrs 6 SD 4 (33) - 24 (60) - 18 (66) -
Packyears. yrs 6 SD 16.669.7 5.963.8 18.7615.3 5.7610.2* 24.4622.3 6.369.1*
Hypercholesterolemia. n (%) 2 (17) - 5 (12.5) - 4 (14.8) 1 (2.5)
Hypertension. n (%) 2 (17) - 6 (15) - 10 (37) 2 (5)*
Acetylsalicylic acid. n (%) 12 (100) - 34 (85) - 19 (70) -
Lipid lowering drugs. n (%) 11 (92) - 38 (95) - 19 (70) 2 (5)*
RAAS-inhibitor. n (%) 4 (33) - 12 (30) - 12 (44) 2 (5)*
Beta blocker. n (%) 5 (42) - 26 (65) - 12 (44) 2 (5)*
doi:10.1371/journal.pone.0025946.t001
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Valdiation cohort I. The 7 differentially expressed miRNAs
identified by the microarray analysis were first validated, by real-
time PCR, in validation cohort I. Of the 7 miRNAs, 2 miRNAs,
miR340* and miR624*, were significantly upregulated in patients
as compared to controls (figure 2).
Validation cohort II. After the first validation, we validated
our results in a second more general cohort of patients of our
premature CAD outpatient clinic. Of the 7 miRNAs identified in
the array analysis, the same 2 miRNAs; miR340* and miR624*,
were significantly upregulated in patients as compared to controls
(figure 2).
We encountered technical difficulties in validating 2 of the 7
miRNAs. MiR615-5p and the only downregulated miRNA,
miR1280, could not be validated, since the PCR primers for
these particular miRNAs did not appear to amplify a specific
product.
Medication use and platelet miRNA expression
To investigate whether medication use might have influenced
the miRNA expression levels of our two candidate miRNAs,
miR340* and miR624*, we also analysed the expression of these
miRNAs. We compared the miRNA expression changes in the
platelet miRNA of controls who took medication for 6 weeks
compared to the expression levels of controls taking no medication
(validation cohort I), as described in the method section; this did
not change the results.
Diagnostic accuracy
When evaluating the combination of 4 candidate miRNAs,
miR340* miR624*, miR451 and miR454*, in our largest vali-
dation cohort (validation cohort I), that the diagnostic accuracy
was AUC=0.71, 95% CI: 0.59–0.83, p,0.002.
Discussion
MiRNA array analysis revealed two platelet-derived miRNAs
(miR624* and miR340*) to be significantly upregulated in patients
with CAD as compared to healthy controls. Besides, these results
could be validated in two independent cohorts.
This is the first study that shows an association between platelet
miRNAs and patients with CAD. Previous studies in humans have
found useful circulating miRNAs as biomarkers for either an acute
myocardial infarction[27–30] or coronary artery disease[31–35].
Concerning myocardial infarction, miR1[27] and miR499[28]
were both detected by array analysis of animal cardiac tissue and
validated in plasma of patients with an acute myocardial
infarction, by qRT-PCR methods. Only recently microarray
analysis of miRNAs on peripheral blood or peripheral blood
components in relation to cardiovascular disease was performed.
The first study by Fichtlscherer et al. [31] investigated plasma
miRNA profiles of 8 patients with CAD and 8 healthy controls.
They found miR-126, miR-17 and miR-92a (endothelial miR-
NAs), miR-155 (inflammatory miRNA) and miR-145 (smooth-
muscle miRNA) to be downregulated in patients as compared to
controls. Furthermore, miR-133a and miR-208a (cardiac-muscle
miRNAs) were significantly upregulated. These results could be
confirmed in 2 different validation cohorts. The second study
investigated whole blood miRNA arrays in relation to an acute
myocardial infarction and found miR-1291 and miR-663b to have
the highest sensitivity and specificity for the discrimination of
cases and controls[29]. In contrast to our study, the above
mentioned human studies were performed on plasma or whole
blood miRNAs and not on platelet miRNAs [15].
Landry et al.[16] were the first to establish the existence and
functionality of miRNA pathway components in platelets of
healthy volunteers. Not only did they show that human platelets
harbour an abundant and diverse array of miRNAs, further
analysis revealed that they also contain the Dicer and Argonaute 2
complexes, which function in the processing of exogenous miRNA
precursors and the control of specific reporter transcripts. These
findings confirm previous studies reporting the presence of
miRNAs in platelet rich plasma, both in healthy donors [22]
and patients with polycythemia vera[20]. On the other hand, these
observations might have been disturbed by leukocyte contami-
nation. Concerning the leukocyte contamination of our study,
we were able to show a platelet purity of 99.72%, therefore
contamination seems highly unlikely. When comparing the
identified miRNAs of Landry with our list of 30 highest expressed
miRNAs of platelets in healthy controls we found that 85% of the
miRNAs expressed in their study are in agreement with our study.
Moreover, when comparing our 30 highest expressed miRNAs of
our platelets in healthy controls with the miRNAs in platelets of
healthy subjects found by Hunter et al.[21], who profiled 420
known mature miRNAs by qRT-PCR, we found an overlap of
48%. Considering the technical differences between our study and
other studies in profiling methods (Illumina beadchips versus
Figure 1. Heatmap. Heatmap of the supervised hierarchical clustering
analysis on the expression profiles of the miRNA array analysis of 24
subjects. Subjects are labelled as either controls (green) or cases (blue)
at the top of the figure (sample identification on x-axis). Names of the
depicted 214 differentially expressed miRNAs (adjusted p,0.05) are
listed in a separate table in the same order (see Data S1 online). The key
colour bar indicates standardized miRNA expression levels (dark red
indicates relatively lower expression; light yellow indicates relatively
higher expression).
doi:10.1371/journal.pone.0025946.g001
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methods (mirVana kit versus Trizol), this overlap is rather large,
supporting the robustness of our data.
It could be argued that usage of medication in our patient
population might have caused the observed differences in miRNA
expression levels. We propose that this is not the case, since our
validation cohort I was evaluated before and after medication use,
which did not influence the results for miR340* and miR624*.
One could speculate which mRNAs are regulated by the two
miRNAs identified in this study. We were, however, not able to
identify any association between these miRNAs and any disease or
tissue involvement.
Regarding the identification of a possible biomarker, the results
of our study are limited. The relatively small differences in miRNA
expression levels between controls and patients make it unlikely
that these miRNAs will serve as independent biomarkers. On the
other hand, a combination of low expressing biomarkers might
exert good prognostic value. Indeed Meder et al. identified a
unique signature of 20 miRNAs that predicted acute myocardial
infarction with higher power and accuracy than any single
miRNAs [29]. With our analysis of the combination of 4 candidate
miRNAs, miR340* miR624*, miR451 and miR454*, we found a
diagnostic accuracy of AUC=0.71, This is in the same range as
the diagnostic accuracy of the Framingham risk score (FRS),
showing that during a 10-year follow-up the FRS was associated
with CVD with an AUC of 0.68 up to 0.77, depending on the
investigated population [36].
In conclusion we show that, years after the onset of CAD,
different platelet miRNA expression patterns exist between
patients and controls. These platelet miRNAs can potentially
fine-tune expression of specific gene products that may be
involved in governing platelet reactivity. Therefore, a dysfunc-
tional miRNA-based regulatory system could lead to the
development of serious platelet-related cardiovascular diseases.
Whether the two identified miRNAs can be used as biomarkers
and whether they are cause or consequence of the disease remains
to be elucidated in a larger prospective study, since the miRNA
array profiling took place after the event in all populations.
Supporting Information
Definitions S1 Definitions with regard to the subjects.
(DOC)
Methods S1 Expanded methods.
(DOC)
Data S1 Names of the depicted 214 differentially expressed
miRNAs (adjusted P,0.05). FC: fold change.
(DOC)
Figure 2. Seven candidate miRNAs expression profiles of platelets from CAD patients and control subjects. Left two bars of each figure
represent average miRNA expression of the miRNA array cohort (12 controls and 12 patients). Validation by real-time PCR was performed on two
independent cohorts (right four bars). Data are presented as mean6SEM and * indicates p,0.05 compared to healthy controls.
doi:10.1371/journal.pone.0025946.g002
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